Quantcast

Nanotechnology-based inhalation treatments for lung cancer: state of the art.

Research paper by Javed J Ahmad, Sohail S Akhter, Md M Rizwanullah, Saima S Amin, Mahfoozur M Rahman, Mohammad Zaki MZ Ahmad, Moshahid Alam MA Rizvi, Mohammad A MA Kamal, Farhan Jalees FJ Ahmad

Indexed on: 08 Dec '15Published on: 08 Dec '15Published in: Nanotechnology, science and applications



Abstract

Considering the challenges associated with conventional chemotherapy, targeted and local delivery of chemotherapeutics via nanoparticle (NP) carriers to the lungs is an emerging area of interest. Recent studies and growing clinical application in cancer nanotechnology showed the huge potential of NPs as drug carriers in cancer therapy, including in lung carcinoma for diagnosis, imaging, and theranostics. Researchers have confirmed that nanotechnology-based inhalation chemotherapy is viable and more effective than conventional chemotherapy, with lesser side effects. Recently, many nanocarriers have been investigated, including liposomes, polymeric micelles, polymeric NPs, solid lipid NPs, and inorganic NPs for inhalation treatments of lung cancer. Yet, the toxicity of such nanomaterials to the lungs tissues and further distribution to other organs due to systemic absorption on inhalation delivery is a debatable concern. Here, prospect of NPs-based local lung cancer targeting through inhalation route as well as its associated challenges are discussed.